Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental immunological screening tests on pidotimod

G Coppi1, S Manzardo

  • 1Research Centre, Poli Industria Chimica S.p.A., Milan, Italy.

Arzneimittel-Forschung
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Choice - Management of Descending Thoracic Aorta Diseases: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS).

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2017
Same author

Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2016
Same author

Transealing: a novel and simple technique for embolization of type 2 endoleaks through direct sac access from the distal stent-graft landing zone.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2014
Same author

INCRAFT® Stent-Graft System: one-year outcome of the INNOVATION Trial.

The Journal of cardiovascular surgery·2013
Same author

BRAVISSIMO: 12-month results from a large scale prospective trial.

The Journal of cardiovascular surgery·2013
Same author

Endovascular treatment of descending thoracic aneurysms.

HSR proceedings in intensive care & cardiovascular anesthesia·2013
Same journal

Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

Arzneimittel-Forschung·2013
Same journal

Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

Arzneimittel-Forschung·2013
Same journal

Leave-one-out procedure in the validation of elimination rate constant analysis.

Arzneimittel-Forschung·2012
Same journal

Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

Arzneimittel-Forschung·2012
Same journal

Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

Arzneimittel-Forschung·2012
Same journal

Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

Arzneimittel-Forschung·2012
See all related articles

Pidotimod, a biological response modifier, effectively restored immune function in mice treated with immunosuppressants. This immunomodulator demonstrated potent activity in both cell-mediated and humoral immunity tests.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Immunosuppression induced by drugs like prednisolone, cyclophosphamide, and methotrexate impairs the immune system.
  • Biological response modifiers offer potential therapeutic strategies to counteract immunosuppression.

Purpose of the Study:

  • To investigate the immunomodulatory effects of Pidotimod in immunosuppressed mice.
  • To evaluate Pidotimod's efficacy in restoring both cell-mediated and humoral immunity.

Main Methods:

  • Administered Pidotimod orally and intraperitoneally to mice with drug-induced immunosuppression.
  • Assessed cell-mediated immunity via rosette formation, lymphocyte proliferation, delayed hypersensitivity, and graft-versus-host reactions.
  • Evaluated humoral immunity through antibody responses to thymus-dependent and independent antigens.

Related Experiment Videos

  • Analyzed macrophage functions, including superoxide production and chemotaxis, and in vivo phagocytic activity.

    • Main Results:

    • Pidotimod significantly restored depressed immune reactivity across all cell-mediated immunity tests.
    • The drug enhanced antibody responses to both thymus-dependent and independent antigens.
    • Pidotimod mitigated the immunosuppressive effects of prednisolone on macrophage functions, restoring chemotaxis.
    • In vivo blood clearance rates in Pidotimod-treated mice normalized to control levels.

    Conclusions:

    • Pidotimod is a potent biological response modifier capable of restoring immune function in states of immunosuppression.
    • Its efficacy spans both cellular and humoral immunity, suggesting broad immunomodulatory capabilities.
    • Pidotimod demonstrates potential as a therapeutic agent to counteract drug-induced immunosuppression.